The Financial Burden of Patient Comorbidities on Total Hip Arthroplasties—A Matched Cohort Analysis of High Comorbidity Burden and Non–High Comorbidity Burden Patients
The Journal of Arthroplasty · 2024
DOI: 10.1016/j.arth.2024.02.052 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Arthroplasty, 2024. Verfasst von Itay Ashkenazi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, NYU Langone Health, New York, New York; Division of Orthopaedic Surgery, Tel-Aviv Sourasky Medical Center, Tel-Avi…. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Hip, Comorbidity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The impact of increased patient comorbidities on the cost-effectiveness of total hip arthroplasty (THAs) is lacking. This study aimed to compare revenue, costs, and short-term (90 days) surgical outcomes between patients who have and do not have a high comorbidity burden (HCB). METHODS: We retrospectively reviewed 14,949 patients who underwent an elective, unilateral THA between 2012 and 2021. Patients were stratified into HCB (Charlson Comorbidity Index ≥ 5 and American Society of Anesthesiology scores of 3 or 4) and non-HCB groups, and were further 1:1 propensity matched based on baseline characteristics. Perioperative data, revenue, costs, and contribution margins (CMs) of the inpatient episode were compared between groups. Also, 90-day readmissions and revisions were compared between groups. Of the 11,717 patients who had available financial data (n = 1,017 HCB, n = 10,700 non-HCB), 1,914 patients were included in the final matched analyses (957 per group). RESULTS: Total (P < .001) and direct (P < .001) costs were significantly higher for HCB patients. Comparable revenue between cohorts (P = .083) resulted in a significantly decreased CM in the HCB patient group (P < .001). The HCB patients were less likely to be discharged home (P < .001) and had significantly higher 90-day readmission rates (P = .049). CONCLUSIONS: Increased THA costs for HCB patients were not matched by increased revenue, resulting in decreased CM. Higher rates of nonhome discharge and readmissions in the HCB population add to the additional financial burden. Adjustments to the current reimbursement models should better account for the increased financial burden of HCB patients undergoing THA and ensure access to care for all patient populations. LEVEL OF EVIDENCE: III.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, NYU Langone Health, New York, New York; Division of Orthopaedic Surgery, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
- Department of Orthopaedic Surgery, NYU Langone Health, New York, New York.
Zitieren
APA
Ashkenazi, I., Thomas, J., Katzman, J., Meftah, M., Davidovitch, R., & Schwarzkopf, R. (2024). The Financial Burden of Patient Comorbidities on Total Hip Arthroplasties—A Matched Cohort Analysis of High Comorbidity Burden and Non–High Comorbidity Burden Patients. The Journal of Arthroplasty. https://doi.org/10.1016/j.arth.2024.02.052
Vancouver
Ashkenazi I, Thomas J, Katzman J, Meftah M, Davidovitch R, Schwarzkopf R. The Financial Burden of Patient Comorbidities on Total Hip Arthroplasties—A Matched Cohort Analysis of High Comorbidity Burden and Non–High Comorbidity Burden Patients. The Journal of Arthroplasty. 2024. doi:10.1016/j.arth.2024.02.052
BibTeX
@article{Ashkenazi2024,
author = {Ashkenazi, Itay and Thomas, Jeremiah and Katzman, Jonathan and Meftah, Morteza and Davidovitch, Roy and Schwarzkopf, Ran},
title = {The Financial Burden of Patient Comorbidities on Total Hip Arthroplasties—A Matched Cohort Analysis of High Comorbidity Burden and Non–High Comorbidity Burden Patients},
journal = {The Journal of Arthroplasty},
year = {2024},
doi = {10.1016/j.arth.2024.02.052}
}
EUVIMED